Rilvegostomig: Data from P3 ARTEMIDE-Gastric01 trial (NCT06764875) for HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma post 2026 (AstraZeneca) - Apr 29, 2025 - Q1 2025 Results
P3 data • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology
|